相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
Melissa M. Berrien-Elliott et al.
BLOOD (2022)
Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity
Bokyung Min et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2022)
CD38 knocKout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Mark Gurney et al.
HAEMATOLOGICA (2022)
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
Wayne L. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
Gianna M. Branella et al.
CELLS (2022)
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Yu Yang Ng et al.
CANCER GENE THERAPY (2022)
Decrease post-transplant relapse using donor-derived expanded NK-cells
Stefan O. Ciurea et al.
LEUKEMIA (2022)
Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) mediate protection against influenza a viral infection
Joseph Gleason et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Mubin Tarannum et al.
FRONTIERS IN IMMUNOLOGY (2022)
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Yang Zhou et al.
CANCERS (2022)
Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products
Brigitte Anliker et al.
CRISPR JOURNAL (2022)
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara J. Laskowski et al.
NATURE REVIEWS CANCER (2022)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Allogeneic, CD34+, Umbilical CordbloodDerived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Michael Heuser et al.
BLOOD (2021)
Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory NonHodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7
Veronika Bachanova et al.
BLOOD (2021)
Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma
Krish Patel et al.
BLOOD (2021)
A Pilot Phase I Trial of IL-21 Expanded IdealDonor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)
Basem M. William et al.
BLOOD (2021)
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
Melita Irving et al.
HUMAN GENE THERAPY (2021)
Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology
Paula Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2021)
Implications of hematopoietic stem cells heterogeneity for gene therapies
Jeremy Epah et al.
GENE THERAPY (2021)
Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
Adrian Fernandez et al.
CANCERS (2021)
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
Kenneth P. Micklethwaite et al.
BLOOD (2021)
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
David C. Bishop et al.
BLOOD (2021)
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila N. Kerbauy et al.
CLINICAL CANCER RESEARCH (2021)
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
Astrid Tschan-Plessl et al.
CYTOTHERAPY (2021)
Infusion reactions in natural killer cell immunotherapy: a retrospective review
Tewodros Mamo et al.
CYTOTHERAPY (2021)
Current Perspectives on Off-The-Shelf Allogeneic NK and CAR-NK Cell Therapies
Erica L. Heipertz et al.
FRONTIERS IN IMMUNOLOGY (2021)
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
Zhicheng Du et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
Kellsye P. Fabian et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
NICOTINAMIDE REJUVENATES EX-VIVO EXPANDED NATURAL KILLER CELLS AND ENHANCES THEIR TUMOR KILLING CAPACITY
Aviad Pato et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
DEVELOPMENT OF WU-NK-101, A FEEDER CELL-FREE EXPANDED ALLOGENEIC MEMORY NK CELL PRODUCT WITH POTENT ANTI-TUMOR ACTIVITY
Ryan Sullivan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
Oscar Fabian Garcia-Aponte et al.
JOURNAL OF BIOLOGICAL ENGINEERING (2021)
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy
Xue Yao et al.
BIODRUGS (2021)
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells
Khaled Sanber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy
Karrune Woan et al.
CELL STEM CELL (2021)
Advances in automated cell washing and concentration
Anqi Li et al.
CYTOTHERAPY (2021)
Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
John M. Wrangle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
Tara Elisabeth Seery et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Comparability: what we can learn from the review of advanced therapy medicinal products
Alexis Cockroft et al.
REGENERATIVE MEDICINE (2021)
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Michelle K. Becker-Hapak et al.
CANCER IMMUNOLOGY RESEARCH (2021)
A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology
Hao-Kang Li et al.
CANCERS (2021)
One-Time Optimization of Advanced T Cell Culture Media Using a Machine Learning Pipeline
Paul Grzesik et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors
Ana L. Portillo et al.
ISCIENCE (2021)
Selecting a Cell Engineering Methodology During Cell Therapy Product Development
Lauren M. Timmins et al.
CELL TRANSPLANTATION (2021)
iPSC-Derived Natural Killer Cells for Cancer Immunotherapy
Peter Karagiannis et al.
MOLECULES AND CELLS (2021)
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Jan Styczynski et al.
BONE MARROW TRANSPLANTATION (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An off the shelf, GMP compliant,fully closed and semi-automated large-scale production system for allogeneic NK cells
J. Veluchamy
CYTOTHERAPY (2020)
HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM)
Farzaneh Sharifzad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients
Mao Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer.
Melissa Ann Geller et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?
Maooz Awan et al.
REGENERATIVE MEDICINE (2020)
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
Rosa Nguyen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
Kento Fujiwara et al.
CELLS (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evaluation of serum -free media formulations in feeder cell stimulated expansion of natural killer cells
Jena E. Moseman et al.
CYTOTHERAPY (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Huang Zhu et al.
CELL STEM CELL (2020)
Vector Copy Distribution at a Single-Cell Level Enhances Analytical Characterization of Gene-Modified Cell Therapies
Ilaria Santeramo et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis
Chengui Lu et al.
MOLECULAR IMMUNOLOGY (2020)
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting
Emanuela M. Iancu et al.
CURRENT OPINION IN BIOTECHNOLOGY (2020)
Sleeping Beauty engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F. Magnani et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
Simone Mantesso et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Tumor Microenvironment-A Metabolic Obstacle to NK Cells' Activity
Joanna Domagala et al.
CANCERS (2020)
A Phase 1 Study of the Combination of MG4101, Ex Vivo-Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma
Dok Hyun Yoon et al.
BLOOD (2020)
Experience with Continuous Infusion of Recombinant Porcine FVIII in Patients with Acquired Hemophilia a
Daniel Lindsay et al.
BLOOD (2020)
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Carlos Bachier et al.
BLOOD (2020)
Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma
Veronika Bachanova et al.
BLOOD (2020)
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy
Frank Cichocki et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)
Janneke Hoogstad-van Evert et al.
MEDICINE (2019)
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao et al.
MOLECULAR THERAPY (2019)
The role of cytokines in the regulation of NK cells in the tumor environment
Gordana M. Konjevic et al.
CYTOKINE (2019)
Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions
Sherien M. El-Daly et al.
JOURNAL OF APPLIED BIOMEDICINE (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Mechanisms of natural killer cell-mediated cellular cytotoxicity
Isabel Prager et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Dean A. Lee
IMMUNOLOGICAL REVIEWS (2019)
Preparation of highly activated natural killer cells for advanced lung cancer therapy
Silun Xie et al.
ONCOTARGETS AND THERAPY (2019)
The Natural Cytotoxicity Receptors in Health and Disease
Alexander David Barrow et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Preservation of cell-based immunotherapies for clinical trials
Rui Li et al.
CYTOTHERAPY (2019)
Towards robust cell culture processes - Unraveling the impact of media preparation by spectroscopic online monitoring
Matthias Brunner et al.
ENGINEERING IN LIFE SCIENCES (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
358PComplete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)
C Nangia et al.
ANNALS OF ONCOLOGY (2019)
Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma
Ning Xia et al.
ANTICANCER RESEARCH (2019)
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Sarah A. Holstein et al.
BLOOD (2019)
Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells
Changjiang Guo et al.
MOLECULAR IMMUNOLOGY (2019)
Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer
Ramesh B. Batchu et al.
SURGERY (2019)
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
Evelyn O. Ojo et al.
SCIENTIFIC REPORTS (2019)
Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15-Implications for Clinical Trials
Heidi Tornroos et al.
ANTICANCER RESEARCH (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
Jode P. Goodridge et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
Robin Parihar et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)
Sarah Cooley et al.
CANCER RESEARCH (2019)
Technical advances in NK cell-based cellular immunotherapy
Fang Fang et al.
CANCER BIOLOGY & MEDICINE (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
Joana M. Murad et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model
In Hye Jung et al.
IN VIVO (2018)
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
Katja Srpan et al.
JOURNAL OF CELL BIOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fetal Bovine Serum (FBS): Past - Present - Future
Jan van der Valk et al.
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION (2018)
Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy
Yiming Meng et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study
Shakeel Modak et al.
ONCOIMMUNOLOGY (2018)
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial
O. Adotevi et al.
ONCOIMMUNOLOGY (2018)
Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells
Masayuki Shiozawa et al.
BMC IMMUNOLOGY (2018)
Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment
Kelong Tao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome
Mohammed Alnaggar et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Adam Ajina et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy
Bokyung Min et al.
IMMUNE NETWORK (2018)
Commercial Scale Manufacturing of Allogeneic Cell Therapy
Gary M. Pigeau et al.
FRONTIERS IN MEDICINE (2018)
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Yuan Hu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
Paulina Nowakowska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Allogeneic cell therapy manufacturing: process development technologies and facility design options
Saeed Abbasalizadeh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
The Broad Spectrum of Human Natural Killer Cell Diversity
Aharon G. Freud et al.
IMMUNITY (2017)
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody
Caroline Jochems et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia A. Wagner et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer
Shuzhen Liang et al.
ONCOTARGETS AND THERAPY (2017)
Development of the First World Health Organization Lentiviral Vector Standard: Toward the Production Control and Standardization of Lentivirus-Based Gene Therapy Products
Yuan Zhao et al.
HUMAN GENE THERAPY METHODS (2017)
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
Markus Granzin et al.
FRONTIERS IN IMMUNOLOGY (2017)
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer immunotherapy: Recent innovations and Future Developments
John P. Veluchamy et al.
FRONTIERS IN IMMUNOLOGY (2017)
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Frank Cichocki et al.
CANCER RESEARCH (2017)
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Sara M. Federico et al.
CLINICAL CANCER RESEARCH (2017)
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells
Aimee C. Talleur et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra et al.
CLINICAL CANCER RESEARCH (2017)
Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells
Anna Domogala et al.
CYTOTHERAPY (2017)
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A consensus introduction to serum replacements and serum-free media for cellular therapies
Ohad Karnieli et al.
CYTOTHERAPY (2017)
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
David L. Hermanson et al.
STEM CELLS (2016)
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
Sabrina Genssler et al.
ONCOIMMUNOLOGY (2016)
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
Inpyo Choi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Aptamers, antibody scFv, and antibody Fab' fragments: An overview and comparison of three of the most versatile biosensor biorecognition elements
Victor Crivianu-Gaita et al.
BIOSENSORS & BIOELECTRONICS (2016)
Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Antonio Curti et al.
CLINICAL CANCER RESEARCH (2016)
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment
Jeremiah L. Oyer et al.
CYTOTHERAPY (2016)
IL-2, IL-7, and IL-15: Multistage regulators of CD4+ T helper cell differentiation
Kaitlin A. Read et al.
EXPERIMENTAL HEMATOLOGY (2016)
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Filippo Milano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann et al.
FRONTIERS IN IMMUNOLOGY (2016)
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial
Colleen Delaney et al.
LANCET HAEMATOLOGY (2016)
CAR models: next-generation CAR modifications for enhanced T-cell function
Daniel Abate-Daga et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Serum-free cell culture: the serum-free media interactive online database
Daniel Brunner
ALTEX-Alternatives to Animal Experimentation (2016)
Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
Markus Granzin et al.
CYTOTHERAPY (2015)
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
Nadja Müller et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
Susann Szmania et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
Naoyuki Sakamoto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Natural killer cell therapy in children with relapsed leukemia
Jeffrey E. Rubnitz et al.
PEDIATRIC BLOOD & CANCER (2015)
The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34+ Hematopoietic Stem and Progenitor Cells
Mieke W. H. Roeven et al.
STEM CELLS AND DEVELOPMENT (2015)
Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial
Hanno M. Specht et al.
FRONTIERS IN IMMUNOLOGY (2015)
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
Nirali N. Shah et al.
BLOOD (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Understanding of molecular mechanisms in natural killer cell therapy
Suk Ran Yoon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2015)
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study
Inpyo Choi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells
Jeffrey W. Leong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Masaru Imamura et al.
BLOOD (2014)
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanova et al.
BLOOD (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
Sawa Ito et al.
MOLECULAR THERAPY (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture
Michael Apel et al.
CHEMIE INGENIEUR TECHNIK (2013)
Irradiated and Activated Autologous PBMCs Induce Expansion of Highly Cytotoxic Human NK Cells In Vitro
Yong-Oon Ahn et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In Vivo
Okjae Lim et al.
PLOS ONE (2013)
Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
Nina Shah et al.
PLOS ONE (2013)
Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
David A. Knorr et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Therapeutic applications: natural killer cells in the clinic
Jeffrey S. Miller
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy
Timo Buhl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy
Martha Luevano et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Natalia Lapteva et al.
CYTOTHERAPY (2012)
The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation
Martha Luevano et al.
HUMAN IMMUNOLOGY (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Concise Review: Genomic Stability of Human Induced Pluripotent Stem Cells
Kristen Martins-Taylor et al.
STEM CELLS (2012)
Concise Review: Cell Therapies: The Route to Widespread Adoption
Lucy Foley et al.
STEM CELLS TRANSLATIONAL MEDICINE (2012)
Targeting natural killer cells and natural killer T cells in cancer
Eric Vivier et al.
NATURE REVIEWS IMMUNOLOGY (2012)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Establishment, Characterization, and Successful Adaptive Therapy Against Human Tumors of NKG Cell, a New Human NK Cell Line
Min Cheng et al.
CELL TRANSPLANTATION (2011)
Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
Mayer N. Fishman et al.
CLINICAL CANCER RESEARCH (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Hua Zhang et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Jan Spanholtz et al.
PLOS ONE (2011)
Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation
David A. Rizzieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Anti-West Nile virus activity of in vitro expanded human primary natural killer cells
Mingjie Zhang et al.
BMC IMMUNOLOGY (2010)
Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
S. R. Yoon et al.
BONE MARROW TRANSPLANTATION (2010)
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Duck Cho et al.
CLINICAL CANCER RESEARCH (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
Mary Eapen et al.
LANCET ONCOLOGY (2010)
Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution
Colleen Delaney et al.
NATURE MEDICINE (2010)
High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
Jan Spanholtz et al.
PLOS ONE (2010)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Maria Berg et al.
CYTOTHERAPY (2009)
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis
Jesse Rowley et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
Loredana Ruggeri et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Data management in the cell therapy production facility: the batch process record (BPR)
W. E. Janssen
CYTOTHERAPY (2008)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
The CD20/αCD20 'suicide' system:: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells
T van Meerten et al.
GENE THERAPY (2006)
Effects of oxygen transport on 3-D human mesenchymal stem cell metabolic activity in perfusion and static cultures: Experiments and mathematical model
F Zhao et al.
BIOTECHNOLOGY PROGRESS (2005)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications
YT Tai et al.
CANCER RESEARCH (2005)
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells
R Gastpar et al.
CANCER RESEARCH (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
KV Konstantinidis et al.
EXPERIMENTAL HEMATOLOGY (2005)
A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization
IM Chen et al.
LEUKEMIA RESEARCH (2004)
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia
MJ Laughlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cell preservation in reparative and regenerative medicine: Evolution of individualized solution composition
AJ Mathew et al.
TISSUE ENGINEERING (2004)
IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation
U Koehl et al.
BLOOD CELLS MOLECULES AND DISEASES (2004)
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells:: a clinical phase I trial
SW Krause et al.
CLINICAL CANCER RESEARCH (2004)
Purification of human natural killer cells using a clinical-scale immunomagnetic method
R Iyengar et al.
CYTOTHERAPY (2003)
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
LJ Burns et al.
BONE MARROW TRANSPLANTATION (2003)
Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood
H Tanaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy
YK Tam et al.
CYTOTHERAPY (2003)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92
G Maki et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus
H Nagata et al.
BLOOD (2001)
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation
M Yagita et al.
LEUKEMIA (2000)